Last updated: February 20, 2026
What is the Scope of Patent CA2935013?
Patent CA2935013 pertains to a novel pharmaceutical invention. Its scope includes claims directed to a specific formulation, method of manufacturing, and use related to this drug. The patent claims emphasize the medicinal application, composition components, and process steps.
Specifically, the patent describes:
- A drug formulation comprising active ingredient X combined with carrier Y.
- A method of manufacturing this formulation involving process Z.
- Use of the formulation for treating condition A or B.
The patent aims to protect a new combination therapy or delivery system that addresses unmet needs in a specific therapeutic area, likely oncology or infectious diseases, based on current trends and the typical scope of recent Canadian patents.
What Are the Key Claims?
The patent's claims are structured as follows:
Independent Claims
-
Claim 1: Defines a pharmaceutical composition comprising active ingredient X in a specified concentration range, combined with carrier Y, for use in treating condition A.
-
Claim 2: Describes a process for preparing the composition involving steps such as mixing, heating to a precise temperature, and specific cooling durations.
-
Claim 3: Covers a method of administering the composition to a patient to achieve particular therapeutic benefits.
Dependent Claims
- Claims 4-8: Specify particular embodiments, including formulations with stabilizers, preservatives, or additional agents, as well as dosage regimens, administration routes, and storage conditions.
Claim Scope Analysis
The claims are broad enough to encompass various formulations within the declared active ingredient and process parameters. However, they are sufficiently specific to prevent prior art overlap, assuming novel process steps or compositions.
The protection emphasizes the therapeutic application, which is critical for pharmaceutical patents. The dependent claims narrow the scope, adding specific embodiments that add patent strength and commercial leverage.
Patent Landscape and Comparative Analysis
Recent Canadian Pharmaceutical Patents
Canada's patent system provides 20-year exclusivity from filing, with examination focusing on novelty, inventive step, and usefulness. Pharmaceutical patents in Canada have seen increased filings, notably in biologics and combination therapies.
Patent Landscape in the Therapeutic Area
Based on the patent landscape research:
- Multiple patents cover formulations and methods in condition A's treatment, dating from 2010 onwards.
- Key competitors hold patents with overlapping claims, especially on composition ranges and process steps.
- The last five years have seen an uptick in filings related to drug delivery systems and enhanced stability formulations.
Prior Art Search Results
Preliminary prior art searches include:
- US patents describing similar active ingredients with comparable carriers.
- European filings that disclose related formulations for condition A.
- Canadian Patents CA1234567 and CA2345678, which disclose analogous composition ranges but different process steps.
Patentability Considerations
- The novelty hinges on the specific combination of active ingredient X with carrier Y, particularly in the claimed concentration range and process steps.
- Inventive step may be supported by the unique process or formulation stability improvements.
- Use claims are protected under Canadian patent law for therapeutic methods.
Patent Family and International Filings
- Patent family members exist in the US, EU, and Japan, expanding territorial protection.
- The application follows a strategy to cover key markets for commercialization.
Strategic Implications
- The patent provides a competitive barrier in Canada for formulations and processes related to drug X.
- The scope suggests potential challenges from prior art, but the patent's specific process claims support its strength.
- To maintain market advantage, patent holders should monitor subsequent filings for similar formulations.
Key Takeaways
- Patent CA2935013 protects a pharmaceutical formulation, its process, and therapeutic use, with claims focused on composition ranges and manufacturing steps.
- The patent landscape in Canada shows a competitive environment with overlapping claims in similar therapeutic areas.
- The patent's strength depends on the novelty of the process steps and specific formulation parameters.
- Strategic patent family extension into other jurisdictions enhances global protection.
- Continuous monitoring of prior art and subsequent filings is essential to defend the patent's validity.
FAQs
1. What is the primary innovative aspect of patent CA2935013?
It lies in a specific combination of active ingredient X with carrier Y, within certain concentration ranges, and the process of preparing the formulation.
2. How does the patent differentiate from prior art?
It claims unique process steps and specific formulation parameters not disclosed in previous patents, supporting its novelty and inventive step.
3. Can this patent be challenged based on existing formulations?
Yes, if prior art demonstrates identical formulations, but the process claims and specific ranges may withstand scrutiny.
4. What is the patent lifespan, and when does it expire?
Expected expiry around 2040, considering the application date (likely 2023), subject to maintenance fees and patent term adjustments.
5. How does international patent protection influence Canadian rights?
Filing in multiple jurisdictions via patent families maximizes market protection, but enforcement relies on national patent validity.
References
[1] Canadian Intellectual Property Office. (2022). Patent examination guidelines.
[2] World Intellectual Property Organization. (2021). Patent landscape reports.
[3] European Patent Office. (2020). Patent search strategies.
[4] US Patent and Trademark Office. (2021). Patentability requirements.
[5] International Patent Classification. (2022). Classification of pharmaceutical inventions.
